Søren Tang Knudsen1, Johan Bodegård2, Kåre I Birkeland3, Kristian Furuseth4, Marcus Thuresson5, Anders Lindh6, Peter M Nilsson7, Michael Alvarsson8, Marit Eika Jørgensen9, Jens Søndergaard10, Frederik Persson11. 1. Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark. 2. AstraZeneca Nordic-Baltic, Oslo, Norway. 3. University of Oslo and Oslo University Hospital, Oslo, Norway. 4. Solli Klinikk, Jessheim, Norway. 5. Statisticon AB, Uppsala, Sweden. 6. Åkersberga, Sweden. 7. Lunds University, Lund, Sweden. 8. Karolinska University Hospital, Stockholm, Sweden. 9. Steno Diabetes Center Copenhagen, Gentofte, Denmark; University of Southern Denmark, Odense, Denmark. 10. University of Southern Denmark, Odense, Denmark. 11. Steno Diabetes Center Copenhagen, Gentofte, Denmark. Electronic address: frederik.persson@regionh.dk.
Abstract
AIMS: To observe and report population demography, comorbidities, risk factor levels and risk factor treatment in a sample of individuals treated for type 2 diabetes in primary care in Norway, Sweden and Denmark. METHODS: Retrospective observational cohort using extraction of data from electronic medical records linked with national health care registries. RESULTS: Sixty primary care clinics participated with annual cross-sectional data (2003 to 2015). In 2015 the sample consisted of 31,632 individuals. Mean age (64.5-66.8 years) and proportion of women (43-45%) were similar. The prevalence of cardiovascular disease in 2015 was 40.7%, 41.6% and 38.0% for Norway, Sweden and Denmark, respectively and 84% to 89% of patients were receiving a pharmacological anti-diabetic treatment. More Danish patients reached targets for HbA1c and LDL cholesterol, while more patients in Sweden and Denmark met the blood pressure target of <130/80 mmHg as compared to Norway. CONCLUSIONS: In three comparable public primary health care systems we found a high prevalence of cardiovascular disease and differences in risk factor treatment and attainment of risk factor goals. With recent guideline changes there is potential for further prevention of diabetes complications in primary care in the future.
AIMS: To observe and report population demography, comorbidities, risk factor levels and risk factor treatment in a sample of individuals treated for type 2 diabetes in primary care in Norway, Sweden and Denmark. METHODS: Retrospective observational cohort using extraction of data from electronic medical records linked with national health care registries. RESULTS: Sixty primary care clinics participated with annual cross-sectional data (2003 to 2015). In 2015 the sample consisted of 31,632 individuals. Mean age (64.5-66.8 years) and proportion of women (43-45%) were similar. The prevalence of cardiovascular disease in 2015 was 40.7%, 41.6% and 38.0% for Norway, Sweden and Denmark, respectively and 84% to 89% of patients were receiving a pharmacological anti-diabetic treatment. More Danish patients reached targets for HbA1c and LDL cholesterol, while more patients in Sweden and Denmark met the blood pressure target of <130/80 mmHg as compared to Norway. CONCLUSIONS: In three comparable public primary health care systems we found a high prevalence of cardiovascular disease and differences in risk factor treatment and attainment of risk factor goals. With recent guideline changes there is potential for further prevention of diabetes complications in primary care in the future.
Authors: Pernille Ravn Jakobsen; Jeanette Reffstrup Christensen; Jesper Bo Nielsen; Jens Søndergaard; Dorte Ejg Jarbøl; Michael Hecht Olsen; Jens Steen Nielsen; Jette Kolding Kristensen; Carl J Brandt Journal: Int J Environ Res Public Health Date: 2021-04-08 Impact factor: 3.390